Navigation Links
Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
Date:3/3/2008

.S. Food and Drug Administration (FDA) in mid-2009.

NicOx has previously completed a clinical study for naproxcinod, which used the 24-hour ABPM monitoring technique to assess the blood pressure profile of naproxcinod in healthy volunteers with stable hypertension (the 104 study) and results of this trial were presented at the American Heart Association (AHA) in November 2007. Today, NicOx announced the initiation of two further studies using the ABPM technique in osteoarthritis patients (see separate press release).

Damian Marron, Executive Vice President of Corporate Development at NicOx, declared: "Beyond naproxcinod, our nitric oxide-donating technology has delivered a broad pipeline of drug candidates in phase 1 and 2, which have highly differentiated profiles and are rapidly advancing through the clinic. These compounds are being developed for serious and prevalent diseases, such as hypertension, glaucoma and COPD, where there is a clear need for improved drugs. According to our forecasts, they have the potential to generate considerable revenues in the mid-to-long term."

Phase 2 proof-of-concept study for PF-03187207 in glaucoma

In March 2007, Pfizer Inc initiated the first phase 2 proof-of-concept clinical study for PF-03187207 in the U.S. and top-line results are expected during April 2008, following the completion of the data analysis. The objective of this study is to compare the safety and efficacy of PF-03187207 to Xalatan (latanoprost). Xalatan is a proprietary Pfizer product and the leader in worldwide glaucoma sales, with approximately $1.6 billion of franchise sales in 2007. A second phase 2 proof-of-concept study was initiated in Japan in January 2008. In February 2007, NicOx and Pfizer presented promising preclinical results from a prototype compound, which is a nitric oxide-donating prostaglandin F2-alpha analog, at the Association for Ocular Pharmacology and Therapeutics 8th Scientific Meeting.

NicOx and Pfizer
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
3. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
4. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Biopure Announces 2007 Third Quarter Financial Results
8. Xytis Names Gordon H. Busenbark as Chief Financial Officer
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Pharmacopeia Announces Third Quarter 2007 Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 McGraw-Hill Education Professional, ... the science, technical, and medical communities, has announced the ... off-line mobile application of the world-renowned medical education platform. ... AccessMedicine App , available for download onto all ... be able to gain access to valuable AccessMedicine ...
(Date:7/29/2014)... New York , July 29, 2014 ... by Transparency Market Research "Orthopedic Trauma Fixation Devices Market ... Analysis 2014 - 2020", the global orthopedic trauma fixation ... 2014 and is expected to grow at a CAGR ... estimated value of USD 9.3 billion in 2020. ...
(Date:7/29/2014)... , July 29, 2014  Instrumentation Laboratory (IL) today ... a new corporate logo. This is part of a comprehensive ... Founded in Boston, MA , in ... of companies since 1992.  Other companies in the group include ... and Systelab ( Barcelona, Spain ).  Like IL, ...
Breaking Medicine Technology:McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
... , STAMFORD, Conn., Nov. 13 ... will be releasing a free trial version of its Zargis ... conference, taking place this November 15-17 in Orlando. Zargis is ... the companion hardware -- the 3M Littmann Electronic Stethoscope Model ...
... BERWYN, Pa., Nov. 13 /PRNewswire-FirstCall/ -- Encorium Group, ... multinational clinical research organization (CRO) conducting studies in over ... and biotechnology companies, today announced that it has appointed ... 7, 2009. Ms. Laitinen, age 43, will replace ...
Cached Medicine Technology:Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 3Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 2Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 3
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 Daily ... that the program was actually created by a popular ... too. He tried numerous treatments for this disorder, but ... found himself in the situation of having to look ... years of research. Dawson used this method, too, to ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... Angeles, CA (PRWEB) July 29, 2014 ... the website of Time Magazine titled “From Kim’s Butt ... Kim Kardashian’s butt is the celebrity feature ... and their features include Beyoncé’s butt, Jennifer Lawrence’s ... lips. This information is based on data collected by ...
(Date:7/29/2014)... 29, 2014 Tylenol lawsuits ( ... allegedly suffered serious liver injuries due to the ... in a multidistrict litigation underway in U.S. District ... reports. According to an Order dated July 23rd, ... to bellwether case and discovery issues. Among other ...
(Date:7/29/2014)... Avenidas is always looking for ... again, the non-profit agency is doing just that with the ... , This event gives seniors the opportunity to learn about ... will be a variety of fun activities, including a Tai ... and artists. In addition, there will be food tastings, courtesy ...
Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2
... Total hip arthroplasty (THA), or hip replacement, is ... studies have only followed patients for up to ... December issue of Arthritis Care & Research ( ... eight years following hip replacement and found a ...
... obtained agreement with the United States, Food and Drug ... SP1049C for the treatment of metastatic adenocarcinoma of the ... upper gastrointestinal tract, ... clinical trial will compare SP1049C plus Best Supportive Care (BSC),versus BSC ...
... Flick, presents World AIDS Day Special ... SIRIUS Satellite Radio,Interview with Madonna and exclusive performances from Cyndi Lauper, Indigo ... Bell and others, NEW YORK, Nov. 28 SIRIUS Satellite Radio,(Nasdaq: ... --,Saturday, December 1 -- with an exclusive broadcast event on SIRIUS OutQ,109, ...
... Over the past few weeks,there has been a ... the meat industry and the USDA that permits ... failed to be "non-negative" for E.,coli O157:H7,( http://www.ehagroup.com/epidemiology/illnesses/e-coli-O157-H7.asp ... includes cooking to the thermal death,stage for all ...
... Breast cancer is a disease with a number ... have seen that these risks are often compounded by ... exactly, do social disadvantages, genetics, race and culture add ... women? , These are among the questions in ...
... of Americans still weigh much too much, study finds , , ... hasn,t increased much in recent years, but there are still ... study reports. , The study, based on 2005-06 data from ... , More than a third of American adults (about 72 ...
Cached Medicine News:Health News:Long-term improvement seen with hip replacement 2Health News:Supratek Pharma Inc. announced today that under the Special Protocol 2Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 2Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 3Health News:The USDA 'E. coli Loophole' in Ground Beef: Much Ado About Nothing 2Health News:The USDA 'E. coli Loophole' in Ground Beef: Much Ado About Nothing 3Health News:New perspectives on health disparities in breast cancer research 2Health News:New perspectives on health disparities in breast cancer research 3Health News:New perspectives on health disparities in breast cancer research 4Health News:New perspectives on health disparities in breast cancer research 5Health News:New perspectives on health disparities in breast cancer research 6Health News:New perspectives on health disparities in breast cancer research 7Health News:New perspectives on health disparities in breast cancer research 8Health News:Obesity Rates Leveling Off Among U.S. Adults 2
... Philadelphia™ Collar and Stabilizer Plastazote® ... reinforcements. Hook-and-pile closure straps. Chin ... mandibular pieces may be interchanged ... easily to the standard Philadelphia ...
Urethrotome - non-optical...
Optical Urethrotome for Telescope 2.7 mm for children....
... The USA Elite ... Visual Urethrotomes are utilized ... strictures and bladder neck ... The visual obturator converts ...
Medicine Products: